Nemes Rush Group’s iShares Biotechnology ETF IBB Stock Holding History

Nemes Rush Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381	Hold	2	–	–	﹤0.01%	920
2026 Q1	$339	Sell	2 -16	-89%	-$2.74K	﹤0.01%	903
2025 Q4	$3.04K	Hold	18	–	–	﹤0.01%	678
2025 Q3	$2.6K	Buy	18 +16	+800%	+$2.18K	﹤0.01%	585
2025 Q2	$253	Sell	2 -6,379	-100%	-$783K	﹤0.01%	704
2025 Q1	$816K	Sell	6,381 -49	-0.8%	-$6.64K	0.1%	97
2024 Q4	$850K	Buy	6,430 +6,019	+1,464%	+$846K	0.11%	98
2024 Q3	$56.4K	Buy	+411	New	+$59.5K	0.01%	250
2024 Q2	–	Sell	-411	Closed	-$56.4K	–	641
2024 Q1	$56.4K	Sell	411 -1,956	-83%	-$267K	0.01%	259
2023 Q4	$322K	Buy	+2,367	New	+$289K	0.05%	136

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Nemes Rush Group's IBB Position: Q2 2026 in Review

Nemes Rush Group held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2 shares worth $381. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Nemes Rush Group first reported a position in IBB in Q4 2023 and has held it in 10 quarters since. The position peaked at $850K in Q4 2024. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Nemes Rush Group held 2 shares of iShares Biotechnology ETF worth $381 as of Q2 2026.
Nemes Rush Group left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #920 holding.
Nemes Rush Group first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 10 quarters since.
Nemes Rush Group's iShares Biotechnology ETF position peaked at $850K in Q4 2024.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.